The BZDs included in this study are presented in supplementary table 1. These were anti-epileptic 102 clonazepam (ATC-code N03AE01), traditional BZD anxiolytics (N05BA), traditional BZD 103 hypnotics (N05CD), BZD related drugs, also called z-hypnotics (N05CF) and combination of 104 chlordiazepoxide and amitriptyline (N06CA01). Purchases of orally administered dosage forms were 105 included in this study with the exception of oral suspensions. i.e. when purchased without special reimbursement for epilepsy. In the Finnish system, patients' 121 entitlement for special reimbursement is based on doctor's certificate fulfilling certain diagnosis 122 criteria. These purchases with special reimbursements are distinguished in a register with special coding. In the non-epileptic indications, the dosing is lower compared to dosing for epilepsy (8mg).
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The dosage of 1mg was used as the defined daily dose for clonazepam use based on the literature and One-year prevalence of BZD use and long-term BZD use were assessed overall and according to . For these prevalence rates, the 95% confidence intervals were calculated. The overall yearly 149 trends of each studied drug were assessed by comparing these confidence intervals. If the confidence 150 intervals were not overlapping, the trend during the assessed period was considered to be statistically Previous studies on BZD use and long-term use have varied considerably in terms of definition for 225 long-term use, time-period of the study and age group making it difficult to compare the prevalence 226 rates between studies. There may also be differences in treatment practices between countries.
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However, prevalence of BZD use (1.9 %) among Finnish young adults in 2014 was similar to that However, results showed that BZDs classified as anxiolytics were more commonly used than 238 hypnotics, which may suggest that BZDs are more often used in anxiety than sleep disorders among 239 young adults. At a substance-level, decreasing trend was observed among almost all BZDs except 240 oxazepam, which was the only substance with increased use. In the last studied year, oxazepam was 241 the most commonly used BZD among Finnish young adults. Increased use of oxazepam may be due 242 to its lower abuse liability (Griffiths et al 1984) . This study found that long-term use among oxazepam 243 users was relatively uncommon. However, a recent study showed that oxazepam users were more ). Yet, in our study, long-term use of BZDs was more prevalent in males than females. This 258 could be partly explained by the previous finding reporting non-medical, e.g. self-reported possible 259 abuse or misuse, use of anxiolytics and hypnotics in adolescence to be significantly more common in 260 males than females in Finland compared to many other European countries (Kokkevi et al 2008) . 261 However, our study did not assess the possible abuse of BZDs. Based on the findings of this study we suggest that patterns of BZD long-term use among young 279 people need more research. Long-term treatment with BZDs can be considered medically justified 280 for some patients. Therefore, it would be of importance to identify specific patient groups, which 281 would benefit from long-term BZD treatment. However, equally important would be to recognize 282 those patients who may experience harm of BZD use. In this first nationwide study on BZD use and long-term use focusing on young adults, we found a 293 declining trend in use and long-term BZD use. Despite this decline, still a nearly one out of five 294 young adult BZD users could be defined as a long-term user and part of this long-term use may also 295 be inappropriate. Our findings urge physicians to pay more attention to BZD prescribing and 296 monitoring for young men who are especially prone to long-term use. In addition, special concern 297 regarding the prescription practices of high potency BZDs alprazolam and clonazepam is needed, as 298 these substances were most commonly used for long-term. 
